Vical to Manufacture SARS Vaccine for U.S.
- Share via
Vical Inc., a San Diego biotechnology company developing infectious-disease treatments, said it signed an agreement with the U.S. to manufacture an experimental SARS vaccine.
Terms were not disclosed. The manufacturing order for a severe acute respiratory disease preventive medicine came from the National Institutes of Health and was in addition to one announced in July for West Nile virus and another in 2002 for the Ebola virus.
Vical shares rose 38 cents to $6.20 on Nasdaq.
Separately, VaxGen Inc., a biotechnology company developing HIV and smallpox vaccines, said it completed a licensing agreement with the U.S. Army for an anthrax vaccine. Shares of Brisbane, Calif.-based VaxGen gained 41 cents, or 3.4%, to $12.44 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
